Advanced Solid Tumor, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Solid Tumor, Renal Pelvis Cancer, Triple Negative Breast Cancer, Urinary Bladder Neoplasm
Conditions
Keywords
Bladder Cancer, Bladder Neoplasm, Bladder Urothelial Carcinoma, Urinary Bladder Cancer, Urinary Tract Cancer, Urothelial Neoplasms, Renal Pelvis Cancer, Ureter Cancer, Nectin-4, Antibody Drug Conjugate (ADC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
Brief summary
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Detailed description
This is a Phase 1a/1b multicenter, open-label study in participants with advanced or metastatic solid tumor malignancies known to express Nectin 4. This study evaluates an antibody-drug conjugate that binds to the protein nectin-4, which is expressed on certain cancer cells, delivering the drug to the cancer. This study is comprised of two phases: Dose Escalation and Dose Optimization (1a), and Dose expansion (1b). Phase 1a will assess the safety, tolerability, and pharmacokinetics of LY4052031 to determine the recommended phase 2 dose (RP2D)/optimal dose. Phase 1b will evaluate efficacy and safety of LY4052031 at the RP2D/optimal dose in expansion cohorts based on tumor type and/or treatment history.
Interventions
DRUGLY4052031
Intravenous
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have one of the following solid tumor cancers: * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer * Cohort A2/B1/B2: urothelial carcinoma * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer * Prior Systemic Therapy Criteria: * Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies * Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies. * Prior enfortumab vedotin specific requirements: * Cohorts A1/A2/C: prior treatment with enfortumab vedotin is allowed, but not required * Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting * Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting. * Measurability of disease * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1) * Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1 * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations
Exclusion criteria
* Individual with known or suspected uncontrolled CNS metastases * Individual with uncontrolled hypercalcemia * Individual with uncontrolled diabetes * Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant * Any serious unresolved toxicities from prior therapy * Significant cardiovascular disease * Recent thromboembolic event and/or clinically significant bleeding disorder * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms * History of pneumonitis/interstitial lung disease * History of Grade ≥3 skin toxicity when receiving enfortumab vedotin * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Cycle 1 (21 Days) | Number of participants with dose-limiting toxicities (DLTs) |
| Phase 1b: To assess the antitumor activity of LY4052031 Monotherapy: Overall response rate (ORR) | Up to Approximately 48 Months or 4 Years | ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To characterize the pharmacokinetics (PK) properties of LY4052031: Minimum Plasma Concentration (Cmin) | Cycle 1 (21 Days) | PK: Cmin of LY4052031 |
| To characterize the PK properties of LY4052031: Area under the concentration versus time curve (AUC) | Cycle 1 (21 Days) | PK: AUC of LY4052031 |
| To evaluate the preliminary antitumor activity of LY4052031: Overall response rate (ORR) | Up to Approximately 48 Months or 4 Years | ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)) |
| To evaluate the preliminary antitumor activity of LY4052031: Duration of response (DOR) | Up to Approximately 48 Months or 4 Years | DOR per investigator assessed RECIST 1.1 |
| To evaluate the preliminary antitumor activity of LY4052031: Time to response (TTR) | Up to Approximately 48 Months or 4 Years | TTR per investigator assessed RECIST 1.1 |
| To evaluate the preliminary antitumor activity of LY4052031: Progression free survival (PFS) | Up to Approximately 48 Months or 4 Years | PFS per investigator assessed RECIST 1.1 |
| To evaluate the preliminary antitumor activity of LY4052031: Disease control rate (DCR) | Up to Approximately 48 Months or 4 Years | DCR per investigator assessed RECIST 1.1 |
| To evaluate the preliminary antitumor activity of LY4052031: Overall survival (OS) | Up to Approximately 48 Months or 4 Years | OS per investigator assessed RECIST 1.1 |
Countries
Australia, China, France, Japan, South Korea, Spain, United Kingdom, United States
Contacts
CONTACTTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACTPhysicians interested in becoming principal investigators please contact
STUDY_DIRECTORCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Outcome results
None listed